PHARMAQ Brand Guidelines: An Overhalla Fish-Vaccine Maker With Alpharma Roots, Now Zoetis

A Norwegian fish-vaccine business bought by its own staff.

PHARMAQ makes vaccines and other health products for farmed fish. Its head office and production plant are at Skogmo, an industrial area in Overhalla in Namdalen, Trøndelag, in central Norway. The Norwegian encyclopaedia Store norske leksikon, in its article on Overhalla, names Pharmaq AS among the businesses in the municipality, producing vaccines and therapeutic products for farmed fish. The company says its production, administration and research and development are all located in Norway, and that its products are sold in Europe, North and South America and Asia, through subsidiaries that include Chile, the United Kingdom, Vietnam, Turkey, Spain, Panama and Hong Kong.

The business is older than the name. When the Norwegian salmon news site iLaks reported a change of owners in March 2013, it described Pharmaq as established in 1985. In the early 2000s the work sat inside the drug company Alpharma Inc., which had an animal health business. In July 2004 Alpharma announced that it had completed the sale of the aquatic animal health operations of that business to an employee group; the release, carried by Bionity on 23 July 2004, said the operations were headquartered in Oslo and made vaccines for immunising farmed fish worldwide. Five days later, on 28 July 2004, The Fish Site reported that PHARMAQ, “a newly formed aquatic health company” headquartered in Norway, had bought Alpharma’s Aquatic Business Unit.

Ownership moved twice in the decade that followed. By 2013 the industrial group Orkla and the investment company Kverva each held 36.64 per cent of Pharmaq Holding, iLaks reported on 31 March 2013, and the two were selling their combined 73.3 per cent to funds advised by Permira, the private equity firm, while the management kept its own shares. Permira’s announcement of the purchase is dated 30 March 2013. On 2 November 2015 Permira announced an agreement to sell PHARMAQ Holding AS to Zoetis, the US animal health company, and Norwegian Wikipedia records that PHARMAQ became part of Zoetis that year. Permira wrote that during its ownership the company had raised its spending on research and development and launched products for new species in emerging markets.

Vaccines, machines and a laboratory.

Today the company presents itself as three businesses under one name. PHARMAQ itself covers vaccines and therapeutics; PHARMAQ Fishteq makes vaccination machinery and equipment; and PHARMAQ Analytiq offers diagnostics and advice. Each has its own section of the company website, with its own “About Us” page, contacts and locations, and all three sit under one shared header that names them side by side.

The vaccines are sold under product names rather than the company name. The online catalogue lists the ALPHA JECT family of injectable vaccines, including several ALPHA JECT micro versions, alongside categories for dip vaccines, therapeutics, biocides and immunosupport. It can be filtered by species — Atlantic salmon, rainbow trout, tilapia, sea bass, pangasius and shrimp among them — and by country, from Norway and Chile to Vietnam, Costa Rica and Greece. That spread fits Permira’s description of the company at its exit, which named Norway, Chile and the UK as core markets and Asia as an emerging one.

Fishteq is the hardware side. The company says it was established in 1995 and that it delivers vaccination technology and services: the NFT fish vaccine machine, the Micro-Matic handheld syringes, and a service in which its own staff carry out vaccination on farms. It says close to 100 NFT machines are in use around the world. Analytiq is a diagnostic laboratory. It says it works from its own laboratories in Oslo, Bergen, Inverness and Puerto Montt, and its list of services includes real-time RT-PCR, histopathology, microbiology and SmoltVision, offered to fish farmers and their health advisers.

The company also gives figures for itself on its home page: 420 employees, 39 years of research and development on fish health and vaccines, and two billion fish vaccine doses delivered in 2025. These are the company’s own numbers. It describes itself as “the global leader in vaccines and innovation for aquaculture”; Permira, when it sold the business, called it “a market leader in aquatic vaccines for farmed fish.”

How aquaculture suppliers present themselves.

Aquaculture suppliers sell to fish farmers and other professional buyers, and their brands are shaped by the places their equipment works. The pictures that recur across the sector are aerial views of circular pens floating in a fjord or a sheltered bay, rows of plastic rings linked by mooring lines, and a feed barge moored beside them. Seen from above, a fish farm is a set of simple shapes on dark water, and many suppliers lean on that geometry in their photography and graphics.

Closer in, the imagery turns to working detail: net cages lifted at the edge of a pen, feed pellets and silos, hoses carrying feed out to the rings, cameras and sensors lowered into the water, and divers or remotely operated vehicles inspecting nets below the surface. Land-based farming adds a different picture, of tanks, pipes and filtration halls indoors. Service boats and workboats appear in many catalogues, because service and maintenance at sea are part of what these suppliers sell.

In many identities colour follows the setting: blues, greens and greys stand in for sea and coast, and a brighter accent, often orange or yellow, echoes the buoys, floats and safety gear that make equipment visible on the water. Type is often a plain sans, chosen for technical documents, product sheets and dashboards as much as for advertising.

Trade fairs remain an important stage for these brands. Aqua Nor in Trondheim and conferences such as AquaVision bring farmers, feed makers and equipment suppliers together, and stands there carry the same mix of pen models, barge cut-aways and screens of feeding software. The guides in this series look at how individual suppliers present themselves within that shared visual language.

A capitalised name with a Q at the end.

The company writes its name in capitals, PHARMAQ, and its two other businesses take the same word as a prefix: PHARMAQ Fishteq and PHARMAQ Analytiq. The Q ending recurs in all three names, so the vaccine maker, the machine maker and the laboratory read as one family even though each sells something different. The product names follow their own line: the ALPHA JECT vaccines and the Micro-Matic syringes carry names of their own rather than the company’s.

Since the 2015 sale the parent has been written into the brand. The company’s “About Us” page is headed “About PHARMAQ part of Zoetis”, the same phrase names its corporate brochure, and the copyright line at the foot of the website belongs to Zoetis. Its page of core beliefs lists principles such as “Always do the right thing” and “Run it like you own it”, and closes with a line about being one Zoetis. The name PHARMAQ, the Overhalla address and the Norwegian base stay in front.

The place is part of the story the company tells. Its website gives the Skogmo industrial area in Overhalla as both head office and production facility on every page, and iLaks described the same Skogmo address as the head office when it reported the Permira purchase in 2013.

For a design guide, PHARMAQ shows how a specialist business can keep its own name inside a much larger parent: the capitals and the Q ending carry the brand, and “part of Zoetis” sits quietly beside it. Compare Zoetis, its owner since 2015, and VAKI, an Icelandic maker of fish-handling equipment that also spent years inside a large animal health group. For this guide we use a deep fjord blue, a sea teal and a pale ice grey with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep PHARMAQ’s identity on hand — save it to a board in the Made Good inspiration library.